Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Editas Medicine (EDIT) EBT Margin (2016 - 2025)

Editas Medicine (EDIT) has disclosed EBT Margin for 11 consecutive years, with 332.97% as the latest value for Q3 2025.

  • On a quarterly basis, EBT Margin rose 10152932.0% to 332.97% in Q3 2025 year-over-year; TTM through Sep 2025 was 426.12%, a 8518.0% decrease, with the full-year FY2024 number at 733.71%, down 53963.0% from a year prior.
  • EBT Margin was 332.97% for Q3 2025 at Editas Medicine, up from 1438.71% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 31.41% in Q4 2023 to a low of 132683.33% in Q3 2022.
  • A 5-year average of 14653.19% and a median of 873.2% in 2021 define the central range for EBT Margin.
  • Peak YoY movement for EBT Margin: crashed -13205237bps in 2022, then soared 13183965bps in 2023.
  • Editas Medicine's EBT Margin stood at 332.3% in 2021, then crashed by -180bps to 929.22% in 2022, then skyrocketed by 97bps to 31.41% in 2023, then tumbled by -372bps to 148.32% in 2024, then plummeted by -124bps to 332.97% in 2025.
  • Per Business Quant, the three most recent readings for EDIT's EBT Margin are 332.97% (Q3 2025), 1438.71% (Q2 2025), and 1624.37% (Q1 2025).